首页> 美国卫生研究院文献>Diabetology Metabolic Syndrome >The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naïve patients with type 2 diabetes mellitus: a randomized controlled trial

【2h】

The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naïve patients with type 2 diabetes mellitus: a randomized controlled trial

机译：二肽基肽酶-4抑制剂沙格列汀在未治疗的2型糖尿病患者中的疗效和安全性：一项随机对照试验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

BackgroundThe aim of this study was to assess efficacy and safety of saxagliptin monotherapy for up to 76 weeks in patients with type 2 diabetes mellitus (T2DM) and inadequate glycemic control, with main efficacy assessment at 24 weeks.

机译：背景本研究的目的是评估沙格列汀单药治疗2型糖尿病（T2DM）和血糖控制不佳的患者的疗效和安全性，最长可达76周，主要疗效评估在24周时进行。

著录项

期刊名称 Diabetology Metabolic Syndrome
作者
Robert Frederich; Robert McNeill; Niklas Berglind; Douglas Fleming; Roland Chen;
展开▼
作者单位

展开▼
年(卷),期 2012(4),-1
年度 2012
页码 36
总页数 12
原文格式 PDF
正文语种
中图分类基础医学;
关键词
DPP-4 inhibitor Monotherapy Saxagliptin Titration Type 2 diabetes mellitus;

机译：DPP-4抑制剂;单一疗法;沙格列汀;滴定法;2型糖尿病;

相似文献

外文文献
中文文献
专利

1. The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-na?ve patients with type 2 diabetes mellitus: a randomized controlled trial [J] . Robert Frederich, Robert McNeill, Niklas Berglind, Diabetology and Metabolic Syndrome . 2012,第12期

机译：二肽基肽酶-4抑制剂沙格列汀在未治疗的2型糖尿病患者中的疗效和安全性：一项随机对照试验
2. Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: A randomised controlled 52-week efficacy and safety study [J] . NowickiM., RychlikI., HallerH., International journal of clinical practice . 2011,第12期

机译：二肽基肽酶-4抑制剂沙格列汀对2型糖尿病和肾功能不全患者的长期治疗：随机对照52周疗效和安全性研究
3. Efficacy and safety of teneligliptin, a novel dipeptidyl peptidase-4 inhibitor, in Korean patients with type 2 diabetes mellitus: a 24-week multicentre, randomized, double-blind, placebo-controlled phase III trial [J] . Hong S., Park C. -Y., Han K. A., Diabetes, obesity & metabolism . 2016,第5期

机译：Teneligliptin（一种新型的二肽基肽酶-4抑制剂）在韩国2型糖尿病患者中的疗效和安全性：一项为期24周的多中心，随机，双盲，安慰剂对照的III期临床试验
4. Fragment-Based Drug Design to Discover Novel Inhibitor of Dipeptidyl Peptidase-4 (DPP-4) as a Potential Drug for Type 2 Diabetes Therapy [C] . Eka Gunarti Ningsih, Muhammad Fauzi Hidayat, Usman Sumo Friend Tambunan International work-conference on bioinformatics and biomedical engineering . 2019

机译：基于片段的药物设计，发现二肽基肽酶-4（DPP-4）的新型抑制剂作为2型糖尿病治疗的潜在药物
5. A 4-month randomized controlled clinical trial of adjuvant Exenatide or Pramlintide versus insulin alone in pediatric type 1 diabetes mellitus: Effect on glycemic control. [D] . Withycombe, Sarah Elizabeth. 2010

机译：儿科1型糖尿病患者中艾塞那肽或普兰林肽与单独使用胰岛素的4个月随机对照临床试验：对血糖控制的影响。
6. Head-to-Head Comparison of the Hypoglycemic Efficacy and Safety Between Dipeptidyl Peptidase-4 Inhibitors and α-Glucosidase Inhibitors in Patients With Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials [O] . Zhaoliang Li, Liang Zhao, Leilei Yu, 2019

机译：二肽肽酶-4型糖尿病患者二肽肽酶-4抑制剂和α-葡萄糖苷酶抑制剂的低血糖疗效和安全性的头脑比较：随机对照试验的荟萃分析
7. The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naïve patients with type 2 diabetes mellitus: a randomized controlled trial [O] . Frederich Robert, McNeill Robert, Berglind Niklas, 2012

机译：二肽基肽酶-4抑制剂沙克列汀治疗初治2型糖尿病患者的疗效和安全性：随机对照试验

The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naïve patients with type 2 diabetes mellitus: a randomized controlled trial

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅